

**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Condensed interim financial statements**  
**As of September 30, 2024**  
**(Reviewed not audited)**

**Index**

|  | <b><u>Page</u></b> |
|--|--------------------|
| Independent auditors' report on review of condensed interim financial statements | 1                  |
| Statement of condensed interim of financial position                             | 2-3                |
| Statement of condensed Interim of comprehensive income                           | 4                  |
| Statement of condensed interim of change in owners' equity                       | 5                  |
| Statement of condensed interim of cash flows                                     | 6                  |
| Notes to condensed interim financial statements                                  | 7-14               |



## Report on the review of the condensed interim financial statements

To the Board of Directors of

Ibn Alhaytham Hospital Co.

Public shareholding company

Amman - The Hashemite Kingdom of Jordan

### Introduction:

We have reviewed the accompanying condensed interim financial statements of **Ibn Al-Haytham Hospital Co.- public shareholding company** comprising of condensed interim statement of financial position as of 30 September 2024, and the related condensed interim statements of comprehensive income, changes in equity and cash flows for nine-month period ended 30 September 2024 and the related explanatory notes.

The management is responsible for the preparation and presentation of these condensed interim financial statements in accordance with IAS 34 – Condensed interim Financial Reporting ("IAS 34"). Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

### Scope of review:

We conducted our review in accordance with International Standard on Review 2410 "Review of Condensed Interim Financial Information Performed by the Independent Auditor of the Entity". A review of the condensed interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with international Standards on Auditing. Consequently, it does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Qualified Conclusion:

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated condensed interim financial statements are not prepared, in all material respects in accordance with IAS 34.

Obeidat & Alsali Co.

Nabeel M. Obeidat

License No. 877

Amman in

October 24, 2024





**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Statement of condensed interim of financial position**  
**as of September 30, 2024 (reviewed not audited)**

|   | <u>Note</u> | <u>30-Sep-2024</u> | <u>31-Dec-2023</u> |
|---|-------------|--------------------|--------------------|
|   |             | JD                 | JD                 |
| <u>Assets</u>   |             | (Reviewed)         | (Audited)          |
| <u>Non - current assets</u>                                 |             |                    |                    |
| Property and Equipment - net                                | 5           | 10,496,789         | 10,660,586         |
| Investments in associates                                   | 6           | 667,535            | 763,153            |
| Projects under construction                                 |             | 2,097,018          | 2,107,278          |
| Down payments on solar project account                      |             | 1,184,570          | 1,184,570          |
| Financial assets at fair value through comprehensive income | 7           | 3,242,834          | 3,465,295          |
| <b>Total non - current assets</b>                           |             | <b>17,688,746</b>  | <b>18,180,882</b>  |
| <u>Current assets</u>                                       |             |                    |                    |
| Medical and non-medical supplies warehouse                  |             | 2,252,483          | 1,742,356          |
| Accounts receivable - net                                   | 8           | 9,026,938          | 8,397,085          |
| Due from related parties                                    | 14 A        | 98,061             | 425,623            |
| Other debit balances  |             | 542,114            | 501,732            |
| Cash on hand and at banks                                   |             | 109,298            | 297,392            |
| <b>Total current assets</b>                                 |             | <b>12,028,894</b>  | <b>11,364,188</b>  |
| <b>Total assets</b>   |             | <b>29,717,640</b>  | <b>29,545,070</b>  |

**The accompanying notes form from (1) To (17) is an integral part of these statements**



**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Follow-Statement of condensed interim of financial position**  
**as of September 30, 2024 (reviewed not audited)**

|  | Note | 30-Sep-2024<br>JD<br>(Reviewed) | 31-Dec-2023<br>JD<br>(Audited) |
|--|------|---------------------------------|--------------------------------|
| <b><u>Owners' equity and liabilities</u></b> |      |                                 |                                |
| <b><u>Owners' equity</u></b>                 |      |                                 |                                |
| Authorized & paid-up capital                 |      | 20,000,000                      | 20,000,000                     |
| Issuance premium                             |      | 1,911,328                       | 1,911,328                      |
| Statutory reserve                            |      | 1,445,544                       | 1,445,544                      |
| Voluntary reserve                            |      | 78,853                          | 78,853                         |
| Fair value reserve                           |      | ( 2,001,428)                    | ( 1,677,501)                   |
| Accumulated (losses)                         |      | ( 7,663,087)                    | ( 7,354,706)                   |
| profit for the period                        |      | 49,479                          | -                              |
| <b>Net owner's equity</b>                    |      | <b>13,820,689</b>               | <b>14,403,518</b>              |
| <b><u>Non-current liabilities</u></b>        |      |                                 |                                |
| Loans - long term                            | 9    | 1,253,710                       | 64,050                         |
| Deffered cheques - long term                 |      | 376,190                         | 95,974                         |
| <b>Total non-current liabilities</b>         |      | <b>1,629,900</b>                | <b>160,024</b>                 |
| <b><u>Current liabilities</u></b>            |      |                                 |                                |
| Banks overdraft                              | 10   | 5,991,541                       | 5,584,152                      |
| Loans - short term                           | 9    | 1,880,977                       | 3,171,277                      |
| Accounts payable                             |      | 4,202,075                       | 3,790,172                      |
| Deffered cheques - short term                |      | 205,836                         | 561,823                        |
| Other credit balances                        |      | 1,986,622                       | 1,874,104                      |
| <b>Total current liabilities</b>             |      | <b>14,267,051</b>               | <b>14,981,528</b>              |
| <b>Total owners' equity and liabilities</b>  |      | <b>29,717,640</b>               | <b>29,545,070</b>              |

**The accompanying notes form from (1) To (17) is an integral part of these statements**

**Ibn-Alhaytham Hospital Co ( P.S.C)****Public shareholding company****Amman - The Hashemite Kingdom of Jordan****Statement of condensed interim of comprehensive income****For the nine months ended September 30, 2024 (reviewed not audited)**

|   | Note | For the nine months ended |                    | For the three months ended |                   |
|---|------|---------------------------|--------------------|----------------------------|-------------------|
|   |      | 30-Sep-2024               | 30-Sep-2023        | 30-Sep-2024                | 30-Sep-2023       |
|   |      | JD                        | JD                 | JD                         | JD                |
|   |      | (Reviewed)                | (Reviewed)         | (Reviewed)                 | (Reviewed)        |
| Revenues  |      | 8,885,844                 | 8,777,752          | 3,129,664                  | 3,385,270         |
| Cost of Revenue   |      | (6,034,167)               | (6,631,168)        | (2,160,535)                | (2,577,216)       |
| <b>Gross Profit Margin</b>  |      | <b>2,851,677</b>          | <b>2,146,584</b>   | <b>969,129</b>             | <b>808,054</b>    |
| General & administrative expenses   |      | (2,022,581)               | (1,973,607)        | (729,338)                  | (500,554)         |
| Depreciation  |      | (502,350)                 | (765,035)          | (152,387)                  | (224,167)         |
| The company's share in the profits of the associates                        | 6 B  | 5,854                     | 11,497             | -                          | -                 |
| Finance expenses  |      | (583,834)                 | (494,815)          | (205,585)                  | (185,358)         |
| Other revenues  |      | 300,713                   | 319,461            | 47,570                     | 78,865            |
| <b>Profit (loss) of the period before tax</b>                               |      | <b>49,479</b>             | <b>(755,915)</b>   | <b>(70,611)</b>            | <b>(23,160)</b>   |
| Income tax  |      | -                         | -                  | -                          | -                 |
| <b>Profit (loss) period</b>   |      | <b>49,479</b>             | <b>(755,915)</b>   | <b>(70,611)</b>            | <b>(23,160)</b>   |
| <b><u>Add: other comprehensive income items</u></b>                         |      |                           |                    |                            |                   |
| Net changes in fair value for financial assets through comprehensive income |      | (323,927)                 | (385,529)          | 13,793                     | (62,001)          |
| <b>Total comprehensive (loss) for the period</b>                            |      | <b>(274,448)</b>          | <b>(1,141,444)</b> | <b>(56,818)</b>            | <b>(85,161)</b>   |
|   |      | <b>Fils/Dinar</b>         | <b>Fils/Dinar</b>  | <b>Fils/Dinar</b>          | <b>Fils/Dinar</b> |
| <b>Basic and diluted earning(loss) per share</b>                            | 12   | <b>0.002</b>              | <b>(0.038)</b>     | <b>(0.004)</b>             | <b>(0.004)</b>    |

**The accompanying notes form from (1) To (17) is an integral part of these statements**

**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Statement of condensed interim of changes in owners' equity**

**For the nine months ended September 30, 2024 (reviewed not audited)**

| Description   | Accumulated (loss) (Loss) for the period |                  |                   |                   |                    |                          |            |            |            |                        |
|---|--|------------------|-------------------|-------------------|--------------------|--------------------------|------------|------------|------------|------------------------|
|   |  |                  |                   |                   |                    | Total accumulated (loss) |            |            |            |                        |
|   | Capital                                  | Issuance premium | Statutory reserve | Voluntary reserve | Fair value reserve | Realized                 | Unrealized | Realized   | Unrealized | Net                    |
|   | JD                                       |                  | JD                |                   | JD                 | JD                       | JD         | JD         | JD         | JD                     |
| <b>For the nine months ended September 30, 2024</b> |  |                  |                   |                   |                    |                          |            |            |            |                        |
| Balance as of January 1, 2024 - ( Audited )         | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | (1,677,501)        | (7,368,289)              | 13,583     | -          | -          | (7,354,706) 14,403,518 |
| Prior years' expenses                               | -  | -                | -                 | -                 | -                  | ( 308,381)               | -          | -          | -          | (308,381) (308,381)    |
| Adjusted opening Balance                            | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | ( 1,677,501)       | ( 7,676,670)             | 13,583     | -          | -          | (7,663,087) 14,095,137 |
| profit of the period                                | -  | -                | -                 | -                 | -                  | -                        | -          | 43,625     | 5,854      | 49,479 49,479          |
| Fair value reserve                                  | -  | -                | -                 | -                 | ( 323,927)         | -                        | -          | -          | -          | ( 323,927)             |
| Total Comprehensive (loss)                          | -  | -                | -                 | -                 | (323,927)          | -                        | -          | -          | -          | 49,479 (274,448)       |
| Balance as of September 30, 2024 ( Reviewed )       | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | ( 2,001,428)       | ( 7,676,670)             | 13,583     | 43,625     | 5,854      | (7,613,608) 13,820,689 |
| <b>For the nine months ended September 30, 2023</b> |  |                  |                   |                   |                    |                          |            |            |            |                        |
| Balance as of January 1, 2023 - ( Audited )         | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | (1,233,204)        | (3,724,473)              | 13,583     | -          | -          | (3,710,890) 18,491,631 |
| Prior years' revenues                               | -  | -                | -                 | -                 | -                  | ( 962,905)               | -          | -          | -          | (962,905) (962,905)    |
| Adjusted opening Balance                            | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | ( 1,233,204)       | ( 4,687,378)             | 13,583     | -          | -          | (4,673,795) 17,528,726 |
| (Loss) of the period                                | -  | -                | -                 | -                 | -                  | -                        | -          | ( 767,412) | 11,497     | (755,915) (755,915)    |
| Fair value reserve                                  | -  | -                | -                 | -                 | ( 385,529)         | -                        | -          | -          | -          | (385,529)              |
| Total Comprehensive (loss)                          | -  | -                | -                 | -                 | (385,529)          | -                        | -          | (767,412)  | 11,497     | (755,915) (1,141,444)  |
| Balance as of September 30, 2023 ( Reviewed )       | 20,000,000                               | 1,911,328        | 1,445,544         | 78,853            | ( 1,618,733)       | ( 4,687,378)             | 13,583     | ( 767,412) | 11,497     | (5,429,710) 16,387,282 |

In accordance with the Securities And Exchange Commission's instructions, it is prohibited to dispose of the balance of fair value reserves of financial assets and the balance of unrealized profits by distributing to the company's shareholders, capitalization, extinguishing losses or any other aspect of conduct.

The accompanying notes form from (1) To (17) is an integral part of these statements



**Ibn-Alhaytham Hospital Company****Public shareholding company****Amman - The Hashemite Kingdom of Jordan****Statement of condensed interim of cash flows****for the nine months ended September 30, 2024 (reviewed not audited)**

|   | Note | 30-Sep-2024<br>JD<br>(Reviewed) | 30-Sep-2023<br>JD<br>(Reviewed) |
|---|------|---------------------------------|---------------------------------|
| <b><u>Cash flows from operating activities</u></b>                    |      |                                 |                                 |
| Profit (Loss) for the period before tax                               |      | 49,479                          | ( 755,915)                      |
| Prior (expenses) years'   |      | ( 308,381)                      | ( 962,905)                      |
| Depreciations   | 5    | 1,014,372                       | 1,323,387                       |
| Company's share of associates peofit                                  | 6    | ( 5,854)                        | ( 11,497)                       |
| <b>Operating profit (loss) before change in working capital items</b> |      | <b>749,616</b>                  | <b>(406,930)</b>                |
| <b><u>(Increase) decrease in current assets</u></b>                   |      |                                 |                                 |
| Accounts receivable   |      | ( 629,853)                      | ( 559,212)                      |
| Due from related parties  |      | 327,562                         | ( 315,398)                      |
| Medical and non-medical supplies warehouse                            |      | ( 510,127)                      | ( 53,100)                       |
| Other debit balances  |      | ( 40,382)                       | 36,243                          |
| <b><u>Increase (decrease) in current liabilities</u></b>              |      |                                 |                                 |
| Accounts payable and deffered Cheques                                 |      | 336,138                         | 60,823                          |
| Other credit balances   |      | 112,518                         | ( 2,683,464)                    |
| <b>Net cash flows provided from (used in) operating activities</b>    |      | <b>345,472</b>                  | <b>(3,921,038)</b>              |
| <b><u>Cash flows from investing activities</u></b>                    |      |                                 |                                 |
| Acquisitions of property , plant & equipments                         | 5    | ( 850,575)                      | ( 130,303)                      |
| Projects under construction   |      | 10,260                          | -                               |
| <b>Net cash flows (used in) investing activities</b>                  |      | <b>(840,315)</b>                | <b>(130,303)</b>                |
| <b><u>Cash flows from financing investing</u></b>                     |      |                                 |                                 |
| Banks overdraft   |      | 407,389                         | 2,984,593                       |
| Loans   |      | ( 100,640)                      | 1,157,991                       |
| <b>Net cash flows provided from financing activities</b>              |      | <b>306,749</b>                  | <b>4,142,584</b>                |
| <b>Net (decrease) increase in cash balances</b>                       |      | <b>(188,094)</b>                | <b>91,243</b>                   |
| Cash on hand & at banks at beginning of Period                        |      | 297,392                         | 193,203                         |
| <b>Cash on hand &amp; at banks at ending of Period</b>                |      | <b>109,298</b>                  | <b>284,446</b>                  |

The accompanying notes form from (1) To (17) is an integral part of these statements

**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Notes to The condensed interim financial statements - reviewed not audited**

---

**1- Company's registration and objectives**

**Ibn-Alhaytham Hospital Company** was established & registered as a Limited Liability company under number (3153) on **April 21,1993** , with a capital amounted (JD **400,000**) divided to ( **400,000** share) and it was increas to amounted to ( JD **20,000,000**).

The company has been converted into a public shareholding company and was registerd aunder number (**436**) in accordance to approval of Ministry of Industry and Trade at **May 10,2007**.

One of company's main objectives is to found and establish a hospital for general casses And especially ophthalmology,Otorhinolaryngology, Medicine and Neurosurgery and to Import a necessary medical equipment and supplies

The condensed interim financial statements were approved by the board of directors at its meeting held on **October 24, 2024** , these financial statements aren't subject to the approval of the general assembly of shareholders .

**2- Basis of preparation of interim financial statements**

These condensed interim financial statement have been prepared in accordance with inernational accounting standards ((IFRS) IAS 34))(Interim Financial Reporting).

The condensed interim financial statements are presented in Jordanian Dinars (JOD) which is the company's presentation functional currency .

The condensed interim financial statements have been prepared on historical cost except financial assets and liabilities which appears on fair value.

These condensed inerim financial statements do not include all the information required for a complete set of IFRS financial statements, However , selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the company's financial position and performance since the last annual report of financial statements as of **December 31, 2023** , in addition, The results for the nine months period ended **September 30, 2024** are not necessarily indicative of the results that may be expected for the financial year ending **December 31, 2024** , and no appropriation was made for the nine months profit ended **September 30, 2024** since it made at the year-end .

**3- Use of estimates**

The preparation of the interim financial statements requires management to make estimates and assumptions that affect the reported amount of financial assets and liabilities and disclosure of contingent liabilities . These estimates and assumptions also affect the revenues and expenses and the resultant provisions and particular , considerable judgement by management is required in the estimation of the amount and timing of future cash flows . Such estimates are necessarily based on assumptions about several factors involving varying degrees of judgment and uncertainty and actual results may differ, resulting in future change in such provisions .

**Notes to The condensed interim financial statements - reviewed not audited**

---

Management believe that the estimates are reasonable and are as follows :

- Management evaluates its investments for impairment on a regular basis where there is a prolonged decline , Management estimates the value of impairment and the same is charged in the statement of comprehensive income - An estimate of the collectible amount of trade accounts receivables is made when collection of the full amount is no longer probable . For individually significant amounts , this estimation is performed on an individual basis . Amounts which are not individually significant , but which are past due , are assessed collectively and a provision applied according to the length of time past due , based on historical recovery rates .
- Inventories are held at the lower of either cost or net realizable value . When inventories become old or obsolete , an estimate is made of their realizable value . For individually significant amounts this estimation is performed on an individual basis . Amounts which are not individually significant , but which are old or obsolete , are assessed collectively and a provision applied according to the inventory type and the degree of aging or obsolescence , based on historical selling prices.
- Management reviews periodically the tangible and intangible assets in order to assess the amortization and depreciation for the year based on the useful life and future economic benefits . Any impairment is taken to the statement of comprehensive income.

**4- Significant accounting policies**

**Changes in accounting policies**

The accounting policies applied in the preparation of the condensed interim financial information for the nine months ended 30 September 2024 are the same as those applied in the preparation of the financial statements for the year ended 31 December 2023, with the exception of International Financial Reporting Standards which became effective as of the years beginning on 1 January 2023.

**New standards or amendments effective from January 1, 2024**

**A) New standards and applicable amendments**

- Classification of liabilities as current or non-current (amendments to IAS 1).
- Lease obligations in sale and lease (amendments to IFRS 16).
- Non-current obligations with collateral (amendments to IAS 1).
- Supplier financing arrangements - amendments to IAS 7 and IFRS 7.
- Non-interchangeability - amendments to IAS 21.
- Sale or contribution to assets between the investor and his associate or joint venture
- Amendments to the International Common Financial Reporting Standard and IAS 28 Investments in associates and joint ventures.

**Following the above amended standards has not materially affected the amounts or disclosures contained in this interim condensed financial information.**

**B) New and amended IFRS issued and not yet in force**

A number of new standards, amendments to standards and interpretations that have been issued but have not yet become effective and have not been applied in the preparation of this condensed interim consolidated financial information:

**New standards and amendments**

Non-interchangeability - amendments to IAS 21.

**Application history**

It comes into effect as of  
From January 1, 2025



**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**  
**Notes to the condensed interim financial statements - reviewed not audited**

**5- Property, plant and equipment - Net**  
This item consists of :

|  | Machines and equipment |            |          |                     |                     |                  |           |           |              |         |            | Total |
|--|------------------------|------------|----------|---------------------|---------------------|------------------|-----------|-----------|--------------|---------|------------|-------|
|  | Lands                  | Buildings  | Vehicles | Medical Equipment's | Furniture & fixture | Office equipment | Computers | Signboard | Other assets |         |            |       |
| <b><u>Cost</u></b>                             | JD                     | JD         | JD       |                     | JD                  | JD               | JD        | JD        | JD           | JD      | JD         | JD    |
| Balance beginning of the period                | 5,373,696              | 12,813,815 | 335,851  | 20,177,407          | 1,199,512           | 1,117,590        | 1,092,799 | 124,038   | 35,855       | 141,726 | 42,412,289 |       |
| Additions                                      | -                      | -          | -        | 161,937             | 647,754             | 22,215           | 12,030    | 6,639     | -            | -       | 850,575    |       |
| Balance ending of the period                   | 5,373,696              | 12,813,815 | 335,851  | 20,339,344          | 1,847,266           | 1,139,805        | 1,104,829 | 130,677   | 35,855       | 141,726 | 43,262,864 |       |
| <b><u>Accumulated depreciations</u></b>        |                        |            |          |                     |                     |                  |           |           |              |         |            |       |
| Balance beginning of the period                | -                      | 10,328,863 | 322,503  | 17,936,115          | 1,052,562           | 1,030,197        | 896,736   | 111,756   | 28,926       | 44,046  | 31,751,704 |       |
| Depreciations                                  | -                      | 333,659    | 4,348    | 508,186             | 64,903              | 37,250           | 59,989    | 3,762     | 1,516        | 759     | 1,014,372  |       |
| Balance ending of the period                   | -                      | 10,662,522 | 326,851  | 18,444,301          | 1,117,465           | 1,067,447        | 956,725   | 115,518   | 30,442       | 44,805  | 32,766,076 |       |
| Book value as of September 30, 2024 (reviewed) | 5,373,696              | 2,151,293  | 9,000    | 1,895,043           | 729,801             | 72,358           | 148,104   | 15,159    | 5,413        | 96,921  | 10,496,789 |       |
| Book value as of December 31, 2023 (audited)   | 5,373,696              | 2,484,952  | 13,348   | 2,241,292           | 146,950             | 87,393           | 196,063   | 12,282    | 6,929        | 97,680  | 10,660,586 |       |

**Ibn Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Notes to The condensed interim financial statements - reviewed not audited**

**6- Investments in associates**

A. This item consists of :

|   | Number of shares |       | Ownership rate | 30-Sep-2024    |            | 31-Dec-2023    |           |
|---|------------------|-------|----------------|----------------|------------|----------------|-----------|
|   | Share            | %     |                | JD             | (Reviewed) | JD             | (Audited) |
| <b>National</b>                                   |                  |       |                |                |            |                |           |
| <b>Limited liability companies (unlisted)</b>     |                  |       |                |                |            |                |           |
| International Co. for Medical Investments **      | 50,710           | 2.167 |                | 50,229         |            | 55,697         |           |
| Alomana' for Investment & portfolio management ** | 666,667          | 7.407 |                | 781,196        |            | 769,654        |           |
| Applied Energy Co. *                              | 100,000          | 40    |                | -              |            | -              |           |
| <b>Total</b>                                      |                  |       |                | <b>831,425</b> |            | <b>825,351</b> |           |
|   |                  |       |                | (163,890)      |            | (62,198)       |           |
| <b>Fair value reserve</b>                         |                  |       |                | <b>667,535</b> |            | <b>763,153</b> |           |
| <b>Fair value</b>                                 |                  |       |                |                |            |                |           |

\* The company's share of associates business results is recorded, and the record stops when the investment's value become zero (in the company's records ( the net equity of associate as of the last audited financial statements was negative).

\*\* The investments were classified above as associates due to the presence of indicators from the investor in influencing the financial and operating decisions of these companies.

**B. The movement of investment in associates during the period as follow :**

|   | 30-Sep-2024 |                | 31-Dec-2023 |                |
|---|-------------|----------------|-------------|----------------|
|   | JD          | (Reviewed)     | JD          | (Audited)      |
| <b>Balance beginning of the period / year</b>           |             | <b>763,153</b> |             | <b>763,170</b> |
| Company's share in the profits of the associates        |             | 5,854          |             | 11,651         |
| Company's share of changes in fair value for associates |             | (101,472)      |             | (11,668)       |
| <b>Balance ending of the period / year</b>              |             | <b>667,535</b> |             | <b>763,153</b> |

**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Notes to The condensed interim financial statements - reviewed not audited**

**7- Financial assets at fair value through comprehensive income statement**

A. This item consists of :

|   | 30-Sep-2024      | 31-Dec-2023      |
|---|------------------|------------------|
| <u>Local</u>                                    | JD               | JD               |
| <u>Public Shareholding Companies (listed)</u>   | (Reviewed)       | (Audited)        |
| Financial assets portfolio                      | 5,071,948        | 5,071,948        |
| <u>Limied liabilities Companies (un-listed)</u> |                  |                  |
| Financial assets portfolio                      | 8,424            | 8,424            |
| <u>Total</u>                                    | <u>5,080,372</u> | <u>5,080,372</u> |
| Deduct : fair value reserve                     | (1,837,538)      | (1,615,077)      |
| <u>Fair value</u>                               | <u>3,242,834</u> | <u>3,465,295</u> |

B. For the purposes of the membership in the boards of directors of some of the invested companies (listed), the number of reserved shares of the owned shares amounted to **140,058** shares and a total market value of JD **223,335**.

**8- Account receivables - net**

A- This item consists of the following:

|  | 30-Sep-2024       | 31-Dec-2023       |
|--|-------------------|-------------------|
|  | JD                | JD                |
|  | (Reviewed)        | (Audited)         |
| Medical receivable   | 13,555,456        | 13,109,631        |
| Trade receivable   | 1,329,849         | 972,399           |
| Personal debts - doctors   | 437,530           | 368,096           |
| Inpatient receivables  | 55,644            | 32,517            |
| Cases debts  | 100,900           | 100,900           |
| Returned checks  | 154,043           | 154,043           |
| Cheques under collection   | 49,927            | 3,500             |
| <u>Total</u>   | <u>15,683,349</u> | <u>14,741,086</u> |
| Deduct: doctor and companies dues (note 8 B)                       | (2,849,165)       | (2,536,746)       |
| <u>Net accounts receivable after doctors' &amp; companies dues</u> | <u>12,834,184</u> | <u>12,204,340</u> |
| Deduct: expected credit losses                                     | (3,807,255)       | (3,807,255)       |
| <u>Net</u>   | <u>9,026,929</u>  | <u>8,397,085</u>  |

B. This item represents doctors' fees for uncollected receivables and suppliers' deposits for special patient supplies required at the request of the patient or the doctor and whose payment is linked to the actual collection of the corresponding receivables.



**Ibn-Alhaytham Hospital Company**  
**Public shareholding company**  
**Amman - The Hashemite Kingdom of Jordan**

**Notes to The condensed interim financial statements - reviewed not audited**

**9- Loans**

A. This Item Consists of :

|                           | 30-Sep-2024      |                  | 31-Dec-2023      |               |
|---------------------------|------------------|------------------|------------------|---------------|
|                           | Short term       | Long term        | Short term       | Long term     |
|                           | JD               | JD               | JD               | JD            |
|                           | (Reviewed)       | (Reviewed)       | (Audited)        | (Audited)     |
| Al-Rajhi Bank (note 10 B) | 1,880,977        | 1,253,710        | 3,135,577        | -             |
| Ittihad Bank (note 10 C)  | -                | -                | 35,700           | 64,050        |
| <b>Total</b>              | <b>1,880,977</b> | <b>1,253,710</b> | <b>3,171,277</b> | <b>64,050</b> |

B. The company obtained loans from Al Rajhi Bank amounting to 3,134,983 Jordanian dinars, in exchange for selling goods to the customer on a term basis, the loan is due under installments with the following maturity dates, 20 November 2024 and 4 December 2024 and 25 March 2025 respectively, and profits of JD 134,983 have been calculated as deferred profits, and the loan was granted against the company's name.

**10- Banks overdraft**

A. This item consists of :

| Bank         | Facilities | Interest rate | Guarantees     | 30-Sep-2024      | 31-Dec-2023      |
|--------------|------------|---------------|----------------|------------------|------------------|
|              | JD         | %             |                | JD               | JD               |
|              |            |               |                | (Reviewed)       | (Audited)        |
| Ittihad Bank | 2,000,000  | 9.75          | Company's name | 2,026,281        | 1,748,185        |
| Arab Bank    | 5,000,000  | 10            |                | 3,965,260        | 3,835,967        |
| <b>Total</b> |            |               |                | <b>5,991,541</b> | <b>5,584,152</b> |

B. Ittihad Bank facilities due date of July 31, 2024 .

C. Arab bank facilities due date of May 31, 2025 .

**11- Income tax**

The company's income tax was accepted for the end of 2021, and income taxes were estimated for the year 2019 at a value of 274,100 dinars, for the year 2020 at a value of 177,161 dinars, and for the year 2021 at a value of 190,201 dinars (with a total value of 641,462 dinars). A request to pay the due amount in installments was submitted and completed. This is approved and the company pays the amount within the schedule agreed upon with the department and in 20 installments starting on April 29, 2023 and ending on November 29, 2024. The income tax self-assessment statement for 2022 and 2023 has been submitted and has not yet been reviewed by the Income and Sales Tax Department.

**12- Basic and diluted earning per share**

This item consists of :

|   | 30-Sep-2024  | 30-Sep-2024    |
|---|--------------|----------------|
|   | JD           | JD             |
| profit (Loss) for the period                      | 49,479       | ( 755,915)     |
| Weighted average shares (share)                   | 20,000,000   | 20,000,000     |
| <b>Basic and diluted earning (loss) per share</b> | <b>0.002</b> | <b>(0.038)</b> |

The diluted earning profit per share is equal to the basic earning per share for the period .

**Ibn-Alhaytham Hospital Company****Public shareholding company****Amman - The Hashemite Kingdom of Jordan****Notes to The condensed interim financial statements - reviewed not audited****13- Contingent liabilities**

On the date of the financial center, the company has contingent liabilities :

|                                   | 30-Sep-2023   | 31-Dec-2023   |
|-----------------------------------|---------------|---------------|
|                                   | JD            | JD            |
|                                   | (Reviewed)    | (Audited)     |
| Bank's guarantees                 | 69,600        | 69,600        |
| Deduct: Bank's gurantees deposits | (5,800)       | (5,800)       |
| <b>Net</b>                        | <b>63,800</b> | <b>63,800</b> |

**14- Related parties transactions**

The related parties represent the main shareholders, associates, subsidiaries, board members and companies in which they are major owners, the prices and conditions related to these transactions are approved by the company's management.

**A. Details of due from related parties appear on financial position**

|   | Type of transaction | 30-Sep-2024   | 31-Dec-2023    |
|---|---------------------|---------------|----------------|
|   |                     | JD            | JD             |
|   |                     | (Reviewed)    | (Audited)      |
| <b><u>Associates</u></b>                                |                     |               |                |
| Inernational Co. for Medical Investments                | Med. Insurance      | 1,235         | 1,210          |
| Arab Int'l Food & Factories & Investments Co.           | Med. Insurance      | 3,051         | 3,050          |
| Ittihad Schools Co.                                     | Med. Insurance      | 29,950        | 46,715         |
| Trans World Information Technology Co.                  | Med. Insurance      | 33            | 33             |
| Jordanian Real Estate Co. for Development               | Med. Insurance      | 662           | 2,291          |
| Arab International Company for education & investment   | Med. Insurance      | 62,168        | 372,017        |
| Alomana Company for Investment and Portfolio Management | Med. Insurance      | 962           | 307            |
| <b>Total</b>  |                     | <b>98,061</b> | <b>425,623</b> |

**B. Details of related parties balances appear on statement of income**

|   | transaction     | 30-Sep-2024    | 30-Sep-2023    |
|---|-----------------|----------------|----------------|
|   |                 | JD             | JD             |
| Arab International Company for education & investment   | Health ins. Rev | 155,694        | 173,480        |
| Alomana Company for Investment and Portfolio Management | Health ins. Rev | 655            | 642            |
| Ittihad Schools Co.                                     | Health ins. Rev | 20,942         | 26,846         |
| Jordanian Real Estate Co. for Development               | Health ins. Rev | 1,048          | 3,060          |
| Apphied energy Co.                                      | Health ins. Rev | -              | 837            |
| <b>Total</b>  |                 | <b>178,339</b> | <b>204,865</b> |

**C. Wages , Allowances and other benefits for senior excutive managements :**

|                             | 30-Sep-2024 | 30-Sep-2023 |
|-----------------------------|-------------|-------------|
|                             | JD          | JD          |
| Salaries and other benefits | 78,255      | 127,176     |

# **Ibn-Alhaytham Hospital Company**

**Public shareholding company**

**Amman - The Hashemite Kingdom of Jordan**

**Notes to The condensed interim financial statements - reviewed not audited**

---

**15- Risk management**

The company is exposed in general to financial risks, credit risks, liquidity risks and market risks, and in general, the goals and policies of the company in managing the financial risks to which the financial statements are exposed, and they have been disclosed in the financial statements as well as the financial statements of the company as well On **December 31, 2023**.

**16- Subsequent events**

There are no subsequent events may have material affects to financial position .

**17- Comparative figures**

Some of the comparative figures have been reclassified to suit the classification of the current fiscal period figures. The reclassification and did not result in any impact on the profit or property rights of the previous year.